Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 15502-15504 [E9-7379]
Download as PDF
15502
Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices
Executive Blvd., Bethesda, MD 20892. (301)
496–8683. singhs@nidcd.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: March 31, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–7718 Filed 4–3–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
pwalker on PROD1PC71 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Training in Clinical
Radiation Therapy Physics and Dosimetry.
Date: April 24, 2009.
Time: 2 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817 ,
(Telephone Conference Call).
Contact Person: Katrin Eichelberg, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892, 301–496–
0818, keichelberg@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical and Pediatric Loan
Repayment Programs.
Date: April 30–May 1, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Erica L. Brown, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
VerDate Nov<24>2008
19:48 Apr 03, 2009
Jkt 217001
MSC 7616, Bethesda, MD 20892–7616, 301–
451–2639, ebrown@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical and Pediatric Loan
Repayment Program.
Date: May 7–8, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Erica L. Brown, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
451–2639, ebrown@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: March 31, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–7721 Filed 4–3–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; Special Emphasis Panel
Review of R25 Applications.
Date: May 20, 2009.
Time: 1 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Mary Kelly, Scientific
Review Officer, Scientific Review Branch,
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
National Institute of Dental & Craniofacial
Research, NIH 6701 Democracy Blvd., Room
672, MSC 4878, Bethesda, MD 20892–4878,
301–594–4809, mary_kelly@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: March 31, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–7723 Filed 4–3–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
E:\FR\FM\06APN1.SGM
06APN1
Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices
The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227. 414–328–
7840/800–877–7016. (Formerly:
Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624.
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118. 901–794–5770/888–290–
1150.
Aegis Sciences Corporation, 345 Hill
Ave., Nashville, TN 37210. 615–255–
2400. (Formerly: Aegis Analytical
Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299. 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center.)
Clendo Reference Laboratory, Avenue,
Santa Cruz #58, Bayamon, Puerto Rico
00959. 787–620–9095.
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802. 800–
445–6917.
Diagnostic Services, Inc., dba DSI,
12700 Westlinks Drive, Fort Myers,
FL 33913. 239–561–8200/800–735–
5416.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602. 229–671–
2281.
pwalker on PROD1PC71 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Nov<24>2008
19:48 Apr 03, 2009
Jkt 217001
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974.
215–674–9310.
DynaLIFE Dx *, 10150–102 St., Suite
200, Edmonton, Alberta, Canada T5J
5E2. 780–451–3702/800–661–9876.
(Formerly: Dynacare Kasper Medical
Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655. 662–
236–2609.
Gamma-Dynacare Medical
Laboratories *, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4. 519–
679–1630.
Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053. 504–
361–8989/800–433–3823. (Formerly:
Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450
Southlake Blvd., Richmond, VA
23236. 804–378–9130. (Formerly:
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040. 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869. 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709.
919–572–6900/800–833–3984.
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group.)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671. 866–827–8042/
800–233–6339. (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219. 913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Maxxam Analytics *, 6740 Campobello
Road, Mississauga, ON, Canada L5N
2L8. 905–817–5700. (Formerly:
Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112.
651–636–7466/800–832–3244.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
15503
MetroLab-Legacy Laboratory Services,
1225 NE. 2nd Ave., Portland, OR
97232. 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417. 612–725–
2088.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304. 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504. 888–747–3774. (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311.
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology
Laboratory.)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204. 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121. 858–643–
5555.
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340.
770–452–1590/800–729–6432.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories.)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403.
610–631–4600/877–642–2216.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories.)
Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405.
866–370–6699/818–989–2521.
(Formerly: SmithKline Beecham
Clinical Laboratories.)
S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109. 505–
727–6300/800–999–5227.
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601. 574–234–4176 x276.
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040. 602–438–8507/800–279–
0027.
Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915.
517–364–7400. (Formerly: St.
Lawrence Hospital & Healthcare
System.)
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101. 405–272–
7052.
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
E:\FR\FM\06APN1.SGM
06APN1
15504
Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices
70 West, Suite 208, Columbia, MO
65203. 573–882–1273.
Toxicology Testing Service, Inc., 5426
NW. 79th Ave., Miami, FL 33166.
305–593–2260.
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235. 301–677–7085.
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Elaine Parry,
Director, Office of Program Services,
SAMHSA.
[FR Doc. E9–7379 Filed 4–3–09; 8:45 am]
BILLING CODE 4160–20–P
safety of navigation. The meeting will be
open to the public.
DATES: NAVSAC will meet on
Wednesday, May 20, 2009, from 8 a.m.
to 5 p.m., and Thursday, May 21, 2009,
from 8 a.m. to 5 p.m. The meeting may
close early if all business is finished.
Written material and requests to make
oral presentations should reach the
Coast Guard on or before May 5, 2009.
Requests to have a copy of your material
distributed to each member of the
committee should reach the Coast Guard
on or before May 5, 2009.
ADDRESSES: NAVSAC will meet at the
Hyatt Regency Savannah, Two West Bay
Street, Savannah, GA 31401. Send
written material and requests to make
oral presentations to Mr. John Bobb, the
Assistant Designated Federal Officer
(ADFO), Commandant (CG–54121), U.S.
Coast Guard Headquarters, 2100 Second
Street, SW., Washington, DC 20593–
0001. This notice may be viewed in our
online docket, USCG–2009–0076, at
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Mr.
Mike Sollosi, the Designated Federal
Officer (DFO) of NAVSAC, telephone
202–372–1545, or e-mail at
mike.m.sollosi@uscg.mil, or Mr. John
Bobb, the ADFO, telephone 202–372–
1532, fax 202–372–1929, or e-mail at
john.k.bobb@uscg.mil.
Notice of
the meeting is given under the Federal
Advisory Committee Act, 5 U.S.C. App.
(Pub. L. 92–493).
SUPPLEMENTARY INFORMATION:
Agenda of Meeting
The agenda for the May 20–21, 2009,
NAVSAC meeting is as follows:
(1) Offshore Renewable Energy
Installations (OREI) NVIC 02–07
Review.
(2) Unmanned Autonomous Vessels
COLREGS Applicability.
(3) Barge Lighting Study.
(4) eNav User Needs Study.
(5) Vessel Traffic System.
Procedural
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2009–0076]
Navigation Safety Advisory Council;
Meeting
Coast Guard, DHS.
Notice of meeting.
pwalker on PROD1PC71 with NOTICES
AGENCY:
ACTION:
SUMMARY: The Navigation Safety
Advisory Council (NAVSAC) will meet
in May 2009 in Savannah, GA, to
discuss various issues relating to the
VerDate Nov<24>2008
19:48 Apr 03, 2009
Jkt 217001
The meeting is open to the public.
Please note that the meeting may close
early if all business is finished. At the
Chair’s discretion, members of the
public may make oral presentations
during the meeting. If you would like to
make an oral presentation at the
meeting, please notify the DFO or ADFO
no later than May 5, 2009. Written
material for distribution at the meeting
should reach the Coast Guard no later
than May 5, 2009. If you would like a
copy of your material distributed to
each member of the committee in
advance of the meeting, please submit
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
20 copies to the DFO or ADFO no later
than May 5, 2009.
Information on Services for Individuals
With Disabilities
For information on facilities or
services for individuals with disabilities
or to request special assistance at the
meeting, contact the DFO or ADFO as
soon as possible.
Dated: March 9, 2009.
Wayne A. Muilenburg,
Captain, U.S. Coast Guard, Office of
Waterways Management.
[FR Doc. E9–7667 Filed 4–3–09; 8:45 am]
BILLING CODE 4910–15–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of Amspec
Services LLC, as a Commercial Gauger
and Laboratory
AGENCY: U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Amspec Services LLC, as a
commercial gauger and laboratory.
SUMMARY: Notice is hereby given that,
pursuant to 19 CFR 151.12 and 19 CFR
151.13, Amspec Services LLC, 12154 B
River Road, St. Rose, LA 70087, has
been approved to gauge and accredited
to test petroleum and petroleum
products, organic chemicals and
vegetable oils for customs purposes, in
accordance with the provisions of 19
CFR 151.12 and 19 CFR 151.13. Anyone
wishing to employ this entity to conduct
laboratory analyses and gauger services
should request and receive written
assurances from the entity that it is
accredited or approved by the U.S.
Customs and Border Protection to
conduct the specific test or gauger
service requested. Alternatively,
inquiries regarding the specific test or
gauger service this entity is accredited
or approved to perform may be directed
to the U.S. Customs and Border
Protection by calling (202) 344–1060.
The inquiry may also be sent to
cbp.labhq@dhs.gov. Please reference the
Web site listed below for a complete
listing of CBP approved gaugers and
accredited laboratories: https://cbp.gov/
xp/cgov/import/operations_support/
labs_scientific_svcs/commercial_
gaugers/.
DATES: The accreditation and approval
of Amspec Services LLC, as commercial
gauger and laboratory became effective
on December 4, 2008. The next triennial
E:\FR\FM\06APN1.SGM
06APN1
Agencies
[Federal Register Volume 74, Number 64 (Monday, April 6, 2009)]
[Notices]
[Pages 15502-15504]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-7379]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
[[Page 15503]]
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Public Law
100-71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227. 414-328-
7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624.
585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis,
TN 38118. 901-794-5770/888-290-1150.
Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210. 615-
255-2400. (Formerly: Aegis Analytical Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299. 501-202-2783. (Formerly: Forensic
Toxicology Laboratory Baptist Medical Center.)
Clendo Reference Laboratory, Avenue, Santa Cruz 58, Bayamon,
Puerto Rico 00959. 787-620-9095.
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802. 800-
445-6917.
Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers,
FL 33913. 239-561-8200/800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602. 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974.
215-674-9310.
DynaLIFE Dx \*\, 10150-102 St., Suite 200, Edmonton, Alberta, Canada
T5J 5E2. 780-451-3702/800-661-9876. (Formerly: Dynacare Kasper Medical
Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655.
662-236-2609.
Gamma-Dynacare Medical Laboratories \*\, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4. 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053.
504-361-8989/800-433-3823. (Formerly: Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, VA
23236. 804-378-9130. (Formerly: Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories, Inc.)
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040. 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869. 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709. 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group.)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671. 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219. 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Maxxam Analytics \*\, 6740 Campobello Road, Mississauga, ON, Canada L5N
2L8. 905-817-5700. (Formerly: Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112.
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE. 2nd Ave., Portland, OR
97232. 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417. 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304. 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504. 888-747-3774. (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311. 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology
Laboratory.)
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204. 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121. 858-
643-5555.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340. 770-452-1590/800-729-6432. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403.
610-631-4600/877-642-2216. (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405.
866-370-6699/818-989-2521. (Formerly: SmithKline Beecham Clinical
Laboratories.)
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109.
505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601. 574-234-4176 x276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040. 602-438-8507/800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915. 517-364-7400. (Formerly: St.
Lawrence Hospital & Healthcare System.)
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101. 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
[[Page 15504]]
70 West, Suite 208, Columbia, MO 65203. 573-882-1273.
Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166.
305-593-2260.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235. 301-677-7085.
\*\ The Standards Council of Canada (SCC) voted to end its
Laboratory Accreditation Program for Substance Abuse (LAPSA) effective
May 12, 1998. Laboratories certified through that program were
accredited to conduct forensic urine drug testing as required by U.S.
Department of Transportation (DOT) regulations. As of that date, the
certification of those accredited Canadian laboratories will continue
under DOT authority. The responsibility for conducting quarterly
performance testing plus periodic on-site inspections of those LAPSA-
accredited laboratories was transferred to the U.S. HHS, with the HHS'
NLCP contractor continuing to have an active role in the performance
testing and laboratory inspection processes. Other Canadian
laboratories wishing to be considered for the NLCP may apply directly
to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 13, 2004 (69 FR 19644).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Elaine Parry,
Director, Office of Program Services, SAMHSA.
[FR Doc. E9-7379 Filed 4-3-09; 8:45 am]
BILLING CODE 4160-20-P